Clinical Trials - Cancer Research Institute (CRI)

About the Cancer Research Institute

The Cancer Research Institute of Scott & White under the leadership of Dr. Arthur Frankel is the leader in Phase I clinical trials for hematological malignancies. There are novel therapies available now to treat t-cell lymphoma, myelodyspastic syndrome and acute myeloid leukemia.

The CRI was established in 2005 to bring new cancer-fighting therapies from the laboratory bench to the patient's bedside in less time than it takes using traditional processes.

The institute is housed in 17,000 square feet within Temple's Health and Bioscience District , and includes laboratories and a Good Manufacturing Practices drug manufacturing facility.

The 37 scientists who comprise the CRI staff are devoted to finding effective therapies for various and rare forms of cancer quickly and cost effectively.

Current clinical trials:

• T-Cell Phase I/II
• Refractory/Relapsed or Elderly/Poor-risk AML
• Acute Lymphoblastic Leukemia

Back to Top